Search Result

Results for "

monoamine oxidase B (MAO-B)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Monoamine Oxidase (74) Adenosine Receptor (1) Amyloid-β (2) Androgen Receptor (1) Apoptosis (4) Autophagy (3) Carbonic Anhydrase (1) Cholinesterase (ChE) (7) Cytochrome P450 (1) Dopamine Receptor (1) Dopamine Transporter (2) Dopamine β-hydroxylase (1) Endogenous Metabolite (3) Ferroptosis (1) Fluorescent Dye (1) Histone Demethylase (2) HSV (2) iGluR (3) Isotope-Labeled Compounds (3) Reactive Oxygen Species (2) Tau Protein (1) α-synuclein (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (5) Infection (5) Inflammation/Immunology (2) Neurological Disease (70)
Click Chemistry:	Alkynes (9)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Monoamine Oxidase Monoamine Transporter Lysyl Oxidase Xanthine Oxidase NADPH Oxidase Protoporphyrinogen IX oxidase VAP-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-123665

PSB-1410	Monoamine Oxidase	Neurological Disease
PSB-1410 is a selective and competitive monoamine oxidase B (MAO-B) inhibitor with IC₅₀ for human MAO-B and rat MAO-B Values are 0.23 and 1.01 nM respectively .

HY-114915

PSB-1434	Monoamine Oxidase	Neurological Disease
PSB-1434 is an inhibitor for monoamine oxidase B (MAO-B), with an IC₅₀ of 1.59 nM .

HY-160002

MAO-B-IN-27	Monoamine Oxidase	Neurological Disease
MAO-B-IN-27 (Compound 12c) is a monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-27 has potent and selective MAO-B inhibitory effect for hMAO-B with an IC₅₀ values of 8.9 nM. MAO-B-IN-27 can be used for the research of parkinson's disease (PD) .

HY-W001601A

Budipine hydrochloride	iGluR	Neurological Disease
Budipine hydrochloride is an anti-parkinson agent. Budipine hydrochloride also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine hydrochloride also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine hydrochloride can be used for the research of CNS disorders include Parkinson disease .

HY-168138

MAO-B-IN-34	Monoamine Oxidase	Cancer
MAO-B-IN-34 (compund 3d) is a monoamine oxidase *MAO-B* inhibitor .

HY-W001601R

Budipine (Standard)	iGluR	Neurological Disease
Budipine (Standard) is the analytical standard of Budipine. This product is intended for research and analytical applications. Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .

HY-147362

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

HY-117502

SL-25.1188	Monoamine Oxidase	Others
SL-25.1188 is a potent **monoamine oxidase B (MAO-B) inhibitor with K_i** values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .

HY-146150

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity .

HY-146149

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity .

HY-151210

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research .

HY-151208

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease .

HY-158732

MAO-B-IN-33	Monoamine Oxidase	Inflammation/Immunology
MAO-B-IN-33 (compound C3) is a potent, reversible and selective **monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀** of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research .

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study .

HY-129444

MD 780236 free base	Monoamine Oxidase	Cancer
MD 780236 free base is a substrate and selective inhibitor of monoamine oxidase B (MAO-B), competitive with phenylethylamine and 5-hydroxytryptamine (5-HT) .

HY-168728

MAO-B-IN-37	Monoamine Oxidase	Neurological Disease
MAO-B-IN-37 (Compound 37) is a derivative of TT01001 (HY-114520), and a selective inhibitor for **monoamine oxidase B (MAO-B) with an IC₅₀** of 270 nM. MAO-B-IN-37 exhibits good metabolic stability in mice microsomes and good affinity with human serum albumin .

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Neurological Disease Cancer
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent **monoamine oxidase (MAO) and aromatase dual inhibitor with IC₅₀*s of 39 nM and 31 nM for MAO-B* and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .

HY-16731

Sembragiline EVT 302; RG1577; RO4602522	Monoamine Oxidase Reactive Oxygen Species	Neurological Disease
Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the *MAO-B* enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased *MAO-B* activity .

HY-W792513

WAY-620147	Monoamine Oxidase	Neurological Disease
WAY-620147 (compound 6) is an N-(2-morpholinoethyl)nicotinamide derivative that inhibits monoamine oxidase (Monoamine Oxidase). WAY-620147 inhibits MAO-A and MAO-B with IC50s of 26 μM and 55 μM, respectively .

HY-N9540

Methyl citrate	Monoamine Oxidase	Neurological Disease
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-163380

CA/MAO-B-IN-1	Carbonic Anhydrase	Neurological Disease
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC₅₀s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated *MAO-B* (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

HY-116765

MAO-B-IN-35	Others	Neurological Disease
MAO-B-IN-35 is a potent, selective, reversible monoamine oxidase B (MAO-B) inhibitor with high inhibitory activity. MAO-B-IN-35 can exhibit high selectivity and potency at a small molecule scale. MAO-B-IN-35 is designed and synthesized so that it can be efficiently obtained during standard synthesis procedures and has superior physical and chemical properties .

HY-116097

PSB-1491	Monoamine Oxidase	Neurological Disease
PSB-1491 is a selective and competitive **monoamine oxidase B (MAO-B) inhibitor with an IC₅₀** of 0.386 nM for hMAO-B. PSB-1491 shows >25000-fold selective versus MAO-A .

HY-161328

MAO-B-IN-31	Monoamine Oxidase α-synuclein Tau Protein	Neurological Disease
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC₅₀ value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .

HY-N13041

Acacetin 7-O-(6-O-malonylglucoside)	Monoamine Oxidase	Neurological Disease
Acacetin 7-O-(6-O-malonylglucoside) is a **monoamine oxidase** inhibitor with strong inhibitory effects on monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) with IC₅₀ values of 2.34 and 1.87 μM, respectively. Acacetin 7-O-(6-O-malonylglucoside) is a reversible *MAO* inhibitor that can be used in the research of neurodegenerative diseases and affective disorders .

HY-162061

ChEs/MAOs-IN-1	Monoamine Oxidase	Neurological Disease
ChEs/MAOs-IN-1 (Compound 4i) is a dual inhibitor of cholinesterases (ChEs) and monoamine oxidases (MAOs).ChEs/MAOs-IN-1 has IC₅₀ values of 0.048 μM, 0.89 μM, 3.58 μM, and 0.095 μM for AChE, BChE, *MAO-B* and *MAO-B* respectively. ChEs/MAOs-IN-1 can be used in the study of neurodegenerative diseases .

HY-U00015

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

HY-162303

C175-0062	Monoamine Oxidase	Neurological Disease
C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .

HY-U00343

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

HY-W205529

RO 16-6491 free base	Fluorescent Dye	Neurological Disease
RO 16-6491 Free base is a selective, reversible inhibitor of monoamine oxidase type B (MAO-B), exhibiting high affinity and specificity for binding sites in human frontal cortex mitochondria and platelet membranes. RO 16-6491 demonstrates a fast dissociation of bound radioactivity at 20 degrees C, indicating its dynamic binding properties. RO 16-6491 also acts as a substrate for MAO-B, suggesting that its oxidation may produce a stable intermediate responsible for its potent inhibitory effects. RO 16-6491 serves as an excellent radioligand probe for investigating the regional tissue distribution of MAO-B in various physiological and pathological states.

HY-157934

MAO-IN-4	Monoamine Oxidase	Neurological Disease
MAO-IN-4 (Compound 2l) is a monoamine oxidase (MAO) inhibitor, with IC₅₀ values of 0.07 and 0.75 μM for MAO-A and MAO-B Enzymes, respectively. MAO-IN-4 can be used for the research of depression and Parkinson’s disease (PD) .

HY-157981

AChE-IN-60	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits **monoamine oxidase (MAO)-A and MAO-B with IC₅₀**s of 353 nM and 716 nM, respectively .

HY-163322

MAO-A inhibitor 2	Monoamine Oxidase	Neurological Disease
MAO-A inhibitor 2 (compound HT4) is a **monoamine oxidase A (MAO-A) inhibitor with an IC₅₀** of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC₅₀ of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research .

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-151094

FTEAA	Monoamine Oxidase	Neurological Disease
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both **monoamine oxidase with IC₅₀*s of 0.52 μM (MAO-A),* 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research .

HY-158092

ChEs/MAOs-IN-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
ChEs/MAOs-IN-2 (compound a11) is a cholinesterases and **monoamine oxidases inhibitor with IC₅₀** values of 0.10, 0.20, 0.30, 0.40 µM for MAO-A, MAO-B, AChE, and BChE, respectively. ChEs/MAOs-IN-2 has the potential for the research of Alzheimer's disease .

HY-B1558A

Bifemelane hydrochloride 1 Publications Verification MCI-2016	Monoamine Oxidase	Neurological Disease
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of **monoamine oxidase A (MAO-A), with a K_i of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a K_i** of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease .

HY-159106

MeSeI	Dopamine Receptor Androgen Receptor Monoamine Oxidase	Neurological Disease
MeSeI exhibits a weak inhibitory activity against monoamine oxidase *MAO-A* and *MAO-B* (IC₅₀=198.8 µM). MeSeI regulates dopamine receptor D2 and norepinephrine receptor α2, β1, and exhibits antidepressant-like effect in mice. MeSeI is orally active .

HY-D0004

Azure B Azure B chloride	Monoamine Oxidase	Neurological Disease
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of **monoamine oxidases (MAO)-A, with IC₅₀*s of 11 and 968 nM for recombinant human MAO-A and MAO-B*, respectively. Azure B possesses significant antidepressant-like effects .

HY-14201

Lazabemide Ro 19-6327	Monoamine Oxidase	Neurological Disease
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide ?inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and?alzheimer′s disease .

HY-14202

Lazabemide hydrochloride Ro 19-6327 hydrochloride	Monoamine Oxidase	Neurological Disease
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of **monoamine oxidase B (MAO-B) (IC₅₀*=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine* uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .

HY-A0091

Pargyline hydrochloride 2 Publications Verification	Monoamine Oxidase	Cardiovascular Disease Cancer
Pargyline hydrochloride is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0091A

Pargyline 2 Publications Verification	Monoamine Oxidase	Cardiovascular Disease Cancer
Pargyline is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103164

(E)-8-(3-Chlorostyryl)caffeine	Adenosine Receptor Monoamine Oxidase	Neurological Disease
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits **monoamine oxidase B (MAO-B) with a K_i** value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research .

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS .

HY-19333

OG-L002 1 Publications Verification	Histone Demethylase Monoamine Oxidase HSV	Infection
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent **monoamine oxidases (MAO) inhibitor with IC₅₀*s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE* genes .

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM .

Cat. No.	Product Name	Type

HY-D0004

Azure B

Azure B chloride

Dyes

Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .

HY-D0004R

Azure B (Standard)

Dyes

Azure B (Standard) is the analytical standard of Azure B. This product is intended for research and analytical applications. Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9540

Methyl citrate	Structural Classification Cactaceae Ketones, Aldehydes, Acids Source classification Opuntia ficus-indica (L.) Mill. Plants	Monoamine Oxidase
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino .

HY-W008566

Norharmane Norharman; β-Carboline	Structural Classification Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Biological Pesticide Research Indole Alkaloids Agricultural Research Infection Alkaloids Microorganisms Disease Research Fields Cancer	Monoamine Oxidase Endogenous Metabolite
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible **monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B*, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings .

HY-N7204

4-Hydroxyderricin 1 Publications Verification	Structural Classification Chalcones Monophenols Flavonoids Phenols Umbelliferae Plants Ondetia linearis Benth.	Monoamine Oxidase Dopamine β-hydroxylase Apoptosis
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is an orally active, potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits dopamine β (DBH)-hydroxylase activity. 4-Hydroxyderricin has antidepressant activity, anti-allergic, anti-diabetic, anti-oxidant, and antitumor effects. 4-Hydroxyderricin promotes apoptosis and cell cycle arrest through regulating PI3K/AKT/mTOR pathway in hepatocellular cells. 4-Hydroxyderricin inhibits osteoclast formation and accelerates osteoblast differentiation . 4-Hydroxyderricin is promising for research of inflammatory diseases .

HY-N13041

Acacetin 7-O-(6-O-malonylglucoside)	Structural Classification Flavonoids Flavones Ligularia veitchiana (Hemsl.) Greenm. Labiatae Source classification Plants	Monoamine Oxidase
Acacetin 7-O-(6-O-malonylglucoside) is a **monoamine oxidase** inhibitor with strong inhibitory effects on monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) with IC₅₀ values of 2.34 and 1.87 μM, respectively. Acacetin 7-O-(6-O-malonylglucoside) is a reversible *MAO* inhibitor that can be used in the research of neurodegenerative diseases and affective disorders .

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Alkaloids Structural Classification Evodia rutaecarpa (Juss.) Benth. Source classification Rutaceae Quinoline Alkaloids Plants	Monoamine Oxidase
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS .

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Alkaloids Neurological Disease Classification of Application Fields Source classification Rutaceae Quinoline Alkaloids Plants Disease Research Fields	Monoamine Oxidase
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM .

HY-W008566R

Norharmane (Standard)	Alkaloids Structural Classification Microorganisms Source classification Pyridine Alkaloids Endogenous metabolite Indole Alkaloids	Monoamine Oxidase Endogenous Metabolite
Norharmane (Standard) is the analytical standard of Norharmane. This product is intended for research and analytical applications. Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC50 values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings .

Cat. No.	Product Name	Chemical Structure

HY-W700241

Norharman-d7

Norharman-d₇ is deuterium labeled Norharmane. Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for MAO-A and MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana seedlings .

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-14605S

Rasagiline-13C3 mesylate
Rasagiline- ¹³C₃ ((R)-AGN1135- ¹³C₃; TVP1012- ¹³C₃) mesylate is the deuterium labeled Rasagiline (mesylate) (HY-14605) . Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively .

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82294

	Monoamine Oxidase B Antibody (YA2039) Adrenalin oxidase; MAO; brain; MAO; platelet; MAOB	WB, IHC-P	Human
	Monoamine Oxidase B Antibody (YA2039) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2039), targeting Monoamine Oxidase B, with a predicted molecular weight of 59 kDa (observed band size: 59 kDa). Monoamine Oxidase B Antibody (YA2039) can be used for WB, IHC-P experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0091

Pargyline hydrochloride 2 Publications Verification		Alkynes
Pargyline hydrochloride is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-A0091A

Pargyline 2 Publications Verification		Alkynes
Pargyline is an irreversible **monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for MAO-A and MAO-B**, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120419

PF9601N		Alkynes
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride		Alkynes
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate		Alkynes
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease . Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605

Rasagiline mesylate Maximum Cited Publications 6 Publications Verification (R)-AGN1135 mesylate; TVP1012 mesylate		Alkynes
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively . Rasagiline (mesylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14605A

Rasagiline Maximum Cited Publications 6 Publications Verification (R)-AGN1135; TVP1012		Alkynes
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively . Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10399

Ladostigil TV-3326		Alkynes
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective **monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE**, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease . Ladostigil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks